Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AXV 101

Next Previous
Drug Profile

AXV 101

Alternative Names: AAV9-BBS1; AXV-101

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Axovia Therapeutics
  • Class Gene therapies
  • Mechanism of Action Bbs1 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bardet-Biedl Syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bardet-Biedl Syndrome

Most Recent Events

  • 04 Sep 2025 The MHRA cleared CTA for AXV 101 in Bardet-Biedl Syndrome
  • 13 May 2025 Pharmacodynamics and adverse event data from a preclinical trial released by Axovia Therapeutics
  • 13 May 2025 Axovia Therapeutics plans a first in human phase I/II trial for Bardet-Biedl Syndrome (Subretinal) in mid 2025 in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top